~ 109 ~ International Journal of Advanced Research in Medicine 2022; 4(2): 109-114 E-ISSN: 2706-9575 P-ISSN: 2706-9567 IJARM 2022; 4(2): 109-114 Received: 08-07-2022 Accepted: 11-08-2022 Dr. (Maj.) Navdeep Garg Gracian Super Speciality Hospital Sector 69, Sahibzada Ajit Singh Nagar, Mohali, Punjab, India Dr. Anish Desai Intellimed Healthcare Solutions, D-213, Kanakia Zillion, Kurla (W), Maharashtra, India Corresponding Author: Dr. Anish Desai Intellimed Healthcare Solutions, D-213, Kanakia Zillion, Kurla (W), Maharashtra, India Functional dyspepsia investigation for gut abnormalities and evaluation of efficacy, safety & time-bound control study with a proprietary blend consisting of clinically proven synergistic poly- botanical extract & Bifidobacterium Infantis (DIGEST study) Dr. (Maj.) Navdeep Garg and Dr. Anish Desai DOI: https://doi.org/10.22271/27069567.2022.v4.i2b.422 Abstract Background: To evaluate the efficacy, safety, and quality of life with a proprietary blend of Herbagut & Bifidobacterium longum in patients with functional dyspepsia and recurrent gut abnormalities (DIGEST study). Methods: In a current Post-marketing Phase IV study, 131 patients with functional dyspepsia were included. All the patients were treated with a proprietary blend consisting of Herbagut & Bifidobacterium longum (Digespur ®, Nutragenix Healthcare Ltd.) twice daily for 28 days. The efficacy of proprietary blend was assessed by evaluating the changes in epigastric pain, early satiety, acidic regurgitation/heartburn, loss of appetite, and retrosternal discomfort. Results: All participants completed the 28-day trial, with no adverse events reported during the study. During the study, treatment with marketed preparation demonstrated significant (p<0.05) improvement in symptoms such as epigastric pain, regurgitation, retrosternal discomfort, sickness, and loss of appetite from the baseline. Furthermore, the proprietary blend also showed improvement in early satiety, nausea and vomiting in functional dyspepsia patients. Conclusion: Treatment with a proprietary blend (Digespur ®) for 28 days showed improvement in several gastrointestinal symptoms and overall quality of life. More research with larger sample sizes and diverse clinical and cultural populations is needed. Keywords: Herbagut, Bifidobacterium longum, functional dyspepsia, satiety, heartburn, etc Introduction Functional dyspepsia is a complex multifactorial condition that affects populations around the globe and is believed to originate as a gastro-duodenal region. The overall prevalence of functional dyspepsia is estimated to be 16%, subject to variation based on the country and criteria used to establish the diagnosis. A higher prevalence i.e. 10% - 40% is encountered in Western countries and around 5% - 30% in Asian countries [1] . Characteristic symptoms of functional dyspepsia include epigastric pain, epigastric burning, postprandial fullness, or early satiety. Female sex, smoking, acute gastroenteritis, Helicobacter pylori infection, non- steroidal anti-inflammatory drug use, and comorbid psychological illness are risk factors for functional dyspepsia. It is generally diagnosed based on the Rome IV criteria. Despite extensive research, the pathophysiological mechanisms underlying functional dyspepsia are complex and poorly explored. Nevertheless, a few mechanisms associated with developing functional dyspepsia are altered gastric motility, altered visceral sensation, psychosocial factors and genetics [2, 3] . Being a chronic gastrointestinal tract disorder, complete remission from functional dyspepsia is a crucial challenge within the healthcare system. It has far-reaching implications on the patient's quality of life and social functioning. Current treatment for functional dyspepsia includes the eradication of Helicobacter pylori infection, prokinetic agents, proton pump inhibitors, H2 receptor antagonists and central neuromodulators [4] . Diet can be a triggering factor and may account for the varied clinical presentation of functional dyspepsia. Considerable heterogeneity in medical literature limits the use of dietary manipulations as a strategy to minimize symptoms among this patient cohort [5] .